Risperidone
- Generic Name
- Risperidone
- Brand Names
- Perseris, Risperdal, Rykindo, Uzedy, Okedi
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27FN4O2
- CAS Number
- 106266-06-2
- Unique Ingredient Identifier
- L6UH7ZF8HC
- Background
Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. Paliperidone, another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone).
...
- Indication
Risperidone is indicated for the treatment of schizophrenia and irritability associated with autistic disorder. It is also indicated as monotherapy, or adjunctly with lithium or valproic acid, for the treatment of acute mania or mixed episodes associated with bipolar I disorder.
...
- Associated Conditions
- Acute Mania, Irritability, Mixed manic depressive episode, Psychosis, Schizophrenia, Acute Manic episode, Agitated psychotic state
- Associated Therapies
- -
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
- Conditions
- Interventions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-05-17
- Lead Sponsor
- Janssen, LP
- Target Recruit Count
- 59
- Registration Number
- NCT00236379
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Yale University
- Registration Number
- NCT00237861
Evaluation of the Usefulness to Doctors of the Risperdal Consta Treatment Guidebook Over a Three-month Period During Which Adult Patients With Schizophrenia or Schizoaffective Disorder Are Switching From Daily Doses or Risperidone Tablets to Long-acting Risperidone by Injection
- Conditions
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2011-05-18
- Target Recruit Count
- 1
- Registration Number
- NCT00236548
A Comparative Study of New Medications for Psychosis in Adolescents
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2006-09-11
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 30
- Registration Number
- NCT00222495
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-12-07
- Lead Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Target Recruit Count
- 99
- Registration Number
- NCT00216632
The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 118
- Registration Number
- NCT00216554
A Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2010-04-27
- Lead Sponsor
- Janssen Korea, Ltd., Korea
- Target Recruit Count
- 527
- Registration Number
- NCT00216528
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
- Conditions
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Central Institute of Mental Health, Mannheim
- Target Recruit Count
- 24
- Registration Number
- NCT00224315
- Locations
- 🇩🇪
Central Institute of Mental Health, Department of Psychiatry,, Mannheim, BW, Germany
A Comparison of Two Standard Therapies in the Management of Dementia With Agitation
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT00208819
- Locations
- 🇺🇸
Wesley Woods Geriatric Hospital, Atlanta, Georgia, United States
Risperidone in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma
- Conditions
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2006-03-10
- Lead Sponsor
- Creighton University
- Target Recruit Count
- 20
- Registration Number
- NCT00208182
- Locations
- 🇺🇸
Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.